{"id":3200,"date":"2026-09-16T07:00:00","date_gmt":"2026-09-16T11:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3200"},"modified":"2026-09-16T20:40:42","modified_gmt":"2026-09-17T00:40:42","slug":"sling-raises-123-million-for-phase-iii-linsitinib","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3200","title":{"rendered":"Sling Raises $123 Million for Phase III Linsitinib"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Sling Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Financing (Series C)<\/p>\n

Platform<\/strong><\/p>\n

Oral Small-Molecule IGF-1R Inhibitor<\/p>\n

Indication<\/strong><\/p>\n

Active Moderate-to-Severe Thyroid Eye Disease<\/p>\n

Summary<\/h4>\n

Sling Therapeutics closed a $123 million Series C led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the 130-participant global Phase III ORBIT trial of oral linsitinib in active moderate-to-severe thyroid eye disease. The financing substantially supports a confirmatory program built on a positive 90-patient LIDS study, while valuation, security terms, ownership, exact runway, and allocation beyond clinical advancement remain undisclosed.<\/p>\n

The announcement was published September 16, 2026 at 7:00 a.m. Eastern and discovered at approximately 8:13 a.m. Eastern. Sling reports that ORBIT has commenced following an End-of-Phase II meeting with FDA. The registry lists a randomized, double-masked, placebo-controlled Phase III study with an open-label extension, estimated enrollment of 130, an August 4, 2026 start, and June 2028 primary completion.<\/p>\n

In the prior LIDS study, 90 patients were randomized to linsitinib 150 mg twice daily, 75 mg twice daily, or placebo. The 150-mg group achieved a 52% proptosis-responder rate at Week 24 with P=0.01; the lower dose did not outperform placebo. The financing disclosure says hearing, glycemic, and menstrual safety were differentiated but does not provide a complete comparative adverse-event table. FDA Fast Track designation accelerates interaction and review eligibility; it does not predict approval.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that the financing syndicate has funded a credible, capital-intensive path to registrational confirmation for an oral therapy against a clinically validated target. A completed randomized study, a defined Phase III design, Fast Track designation, and commencement of ORBIT support that view. Against it, LIDS was small, only one dose succeeded, and the full safety and durability profile remains incomplete. A second interpretation is that the raise reflects the size of a global pivotal program rather than unusually strong scientific conviction. The $123 million amount and named investors indicate substantial diligence, but financing itself does not validate efficacy, safety, market access, or reimbursement.<\/p>\n

Company and Product Background<\/h4>\n

Sling Therapeutics is a private clinical-stage biotechnology company focused on thyroid eye disease. Linsitinib is an oral small-molecule inhibitor of IGF-1R, a signaling node implicated in orbital fibroblast activation, inflammation, and proptosis. The target is clinically validated by approved antibody therapy. An oral agent could reduce infusion burden, but systemic IGF-1R inhibition raises hearing, glucose, reproductive, cardiac, and adherence considerations that require controlled Phase III assessment.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The Series C is strategically material because it couples a large private round to an already-started confirmatory study rather than a discovery promise.<\/li>\n
  • Upgrades with:<\/strong> full LIDS publication, rapid ORBIT enrollment, replicated proptosis and diplopia benefit, durable response, low hearing and metabolic toxicity, and sufficient capital through regulatory submission.<\/li>\n
  • Downgrades with:<\/strong> dose-limiting tolerability, weak adherence to twice-daily oral treatment, placebo variability, delayed enrollment, or capital needs before readout.<\/li>\n
  • Falsified if:<\/strong> Phase III fails to reproduce clinically meaningful benefit or shows no safety or convenience advantage in real use.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The Series C is strategically material because it couples a large private round to an already-started confirmatory study rather than a discovery promise. The positive financing signal remains conditional on ORBIT reproducing the higher-dose LIDS result and demonstrating that oral convenience does not trade away efficacy, adherence, or safety.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 — a $123 million round directly funding an active global Phase III trial. Importance:<\/strong> Positive — new capital and trial commencement improve execution capacity. Confidence:<\/strong> High on facts (round size, investors, use of proceeds, and trial status are confirmed); moderate on interpretation (terms, runway, and complete Phase II evidence remain undisclosed).<\/p>\n","protected":false},"excerpt":{"rendered":"

    Sling Therapeutics closed a $123 million Series C led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the 130-participant global Phase III…<\/p>\n","protected":false},"author":1,"featured_media":3205,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,2],"tags":[779,780,781],"class_list":["post-3200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-deals-and-financing","tag-linsitinib","tag-sling-therapeutics","tag-thyroid-eye-disease"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3200"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3200\/revisions"}],"predecessor-version":[{"id":3218,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3200\/revisions\/3218"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3205"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}